What type of drug does Erdafitinib belong to? Is it a targeted therapy?

Erdafitinib is an oral small molecule targeted therapy drug mainly used to treat advanced or metastatic urothelial cancer with FGFR (fibroblast growth factor receptor) gene mutations or fusions. It blocks the signaling pathways of cancer cells by inhibiting the activity of receptors such as FGFR1, FGFR2, FGFR3, and FGFR4, thereby inhibiting the growth and spread of tumors. Because its mechanism is well understood and it targets specific genetic alterations, erdafitinib is classified as a "precision targeted therapy" drug.

As a targeted therapy drug, the prerequisite for the use of erdafitinib is the presence of specific FGFR gene abnormalities in the patient, especially FGFR2 or FGFR3 fusions or mutations. The drug was approved by the FDA in 2019, becoming the first targeted therapy for bladder cancer targeting FGFR gene mutations. Different from traditional chemotherapy, targeted drugs such as erdafitinib can selectively act on molecular targets related to cancer cells, often have lower side effects and more targeted efficacy, especially for patients who cannot tolerate chemotherapy.

Clinical studies have shown that the objective response rate (ORR) of erdafitinib in patients with previously treated urothelial cancer has reached about 40%, and it has a more significant effect on patients carrying FGFR mutations. However, the drug may also cause some side effects related to the FGFR pathway, such as hyperphosphatemia, ocular toxicity (including retinal disease), and stomatitis, so close monitoring and dose adjustment are required during use. Doctors usually recommend regular blood phosphorus level checks and eye evaluations while taking the medication.

In summary, erdafitinib is a drug that targetsFGFRDrugs that target genetic abnormalities have been used to treat bladder cancer patients with specific genetic mutations. Its development and application mark the progress of precision medicine and bring new hope to some patients who are ineffective or intolerant to traditional treatments. However, since its therapeutic effect is limited by the results of genetic screening, it is recommended that patients undergo comprehensive molecular testing before use and undergo individualized treatment under the guidance of professional doctors.

Reference link:https://www.balversa.com/

xa0